SCHEMBL8517633

SCHEMBL8517633

CCCCc1cc(OCc2ccccc2)c(C(=O)OC(C)(C)C)c2ncnn12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 2/20 0.41
NR1H4 Q96RI1 1/20 0.37
FFAR4 Q5NUL3 1/20 0.35
CYP2C9 P11712 1/20 0.35
EGLN1 Q9GZT9 2/20 0.34
CTSK P43235 1/20 0.34
PTGES O14684 2/20 0.33
ALOX5 P09917 2/20 0.33
TLR7 Q9NYK1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
HPGD P15428 1/20 0.33
HIF1A Q16665 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8517219 0.88 PTGER1 (0.47) PTGER1NR1H4FFAR4EGLN1PTGES
SCHEMBL15744035 0.87 PTGER1 (0.44) PTGER1NR1H4FFAR4CYP2C9EGLN1
SCHEMBL8527782 0.84 CYP2C9 (0.37) PTGER1FFAR4CYP2C9EGLN1TLR7
SCHEMBL8526969 0.82 EGLN2 (0.39) PTGER1FFAR4CYP2C9EGLN1KDM4E
SCHEMBL30599272 0.81 PPARG (0.36) PTGER1FFAR4CYP2C9TLR7KDM4E
SCHEMBL12750386 0.79 ADORA3 (0.35) PTGER1FFAR4CYP2C9PTGESTLR7
SCHEMBL8520838 0.76 CYP2C9 (0.39) PTGER1FFAR4CYP2C9EGLN1TLR7
SCHEMBL8527666 0.76 SMN1; SMN2 (0.38) PTGER1FFAR4CYP2C9KDM4EALDH1A1
SCHEMBL30599273 0.75 ALKBH1 (0.33) PTGER1FFAR4CYP2C9KDM4EALDH1A1
SCHEMBL31563009 0.74 TLR9 (0.33) PTGER1FFAR4CYP2C9TLR7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 EP disclosed
EP-2746282-A1 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer Japan Tobacco Inc. (JP) 2014-06-25 EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885NR1H4 2103/4885FFAR4 4684/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885NR1H4 2103/4885FFAR4 4684/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 PTGER1 1511/4885NR1H4 2103/4885FFAR4 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.